News & Events
-
May 7, 2018
C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)
TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA). The qualification of the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) for exploratory use represents another major milestone for the PRO Consortium and,... - April 27, 2018
-
April 26, 2018
CPTR Newsletter – April 2018
CPTR Newsletter – April 2018 In this issue: ReSeqTB to be Adopted for WHO Surveillance of Drug-Resistant TB New Collaborations Expand TB-PACTS Database and Leverage Data for Analyses CPTR Workgroup Works to Advance Regulatory Qualification of LAM, a Promising New Biomarker TB-PBPK Model Progresses Toward EMA and FDA Qualification TB-ReFLECT Update: A Collaborative Effort... -
April 25, 2018 - April 26, 2018
Ninth Annual Patient-Reported Outcome Consortium Workshop
April 25 – 26, 2018 Sheraton Silver Spring Hotel 8777 Georgia Avenue Silver Spring, MD 20910 On April 25-26, 2018 the NINTH ANNUAL PATIENT-REPORTED OUTCOME CONSORTIUM WORKSHOP was held in Silver Spring, Maryland. The overall Workshop objectives were to: Provide an update on FDA’s Clinical Outcome Assessment (COA) Qualification Program and address changes associated with... -
April 16, 2018
Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease Biomarkers
Tucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path Institute (C-Path) a grant to support a Crohn’s disease biomarker pre-consortium. The pre-consortium will identify unmet needs for the use of biomarkers in developing new treatments for people with Crohn’s disease. Currently,...
